secwatch.observer — SEC 8-K summary
======================================

Issuer:     Krystal Biotech, Inc. (KRYS)
CIK:        0001711279
Form:       8-K
Filed at:   2023-07-26T23:59:59+00:00
Accession:  0001711279-23-000061
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Krystal Biotech expands to oncology; FDA accepts IND for KB707 for solid tumors
-------------------------------------------------------------------------------

- FDA accepted IND for KB707, a modified HSV-1 vector delivering IL-12 and IL-2 for solid tumors.
- Two formulations: intratumoral injection for accessible tumors and inhaled (nebulized) for lung delivery.
- Phase 1 Opal 1 study to start 2H 2023; amendment for inhaled formulation expected in 2H 2023.
- Preclinical data showed antitumor responses in checkpoint-inhibitor-refractory mouse models.
- Investor conference call on July 27, 2023 at 8:00 AM ET to discuss KB707 program.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000061/0001711279-23-000061-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1711279/000171127923000061/krys-20230726.htm
  HTML page:      https://secwatch.observer/filing/0001711279-23-000061

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer